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Abstract
Background: Faecal dysbiosis associated with the use of metformin has been conceived as a favourable (“good”)
dysbiosis and that with intake of non-nutritive sweeteners (NNS) as unfavourable (“bad”). The study aimed to
construct an alternative dysbiosis index (ADI) for the separation of the dysbioses into “good” and “bad”, and to
validate the ADI.
Methods: Subjects with morbid obesity were included. Use of NNS and drugs were noted, IBS was classified
according to the Rome III criteria and the severity measured with the Irritable bowel severity scoring system (IBSSS).
Faecal dysbiosis was tested with GA-Map ™ Dysbiosis test (Genetic Analysis AS, Oslo, Norway). The result was given
as Dysbiosis Index (DI) scores 1–5, score > 2 indicates dysbiosis. An ADI was constructed and validated in subjects
with IBS at another hospital.
Results: Seventy-six women and 14 men aged 44.7 years (SD 8.6) with BMI 41.8 kg/m2 (SD 3.6) were included.
Dysbiosis was associated with the use of NNS and metformin, but not with IBS or IBSSS. An ADI based on
differences in 7 bacteria was positively and negatively associated with the “good” metformin dysbiosis and the
“bad” NNS dysbiosis respectively. The ADI was also negatively associated with IBSSS (a “bad” dysbiosis). The negative
associations between ADI and IBS and IBSS were confirmed in the validation group.
Conclusions: The new ADI, but not the DI, allowed separation of the “good” and “bad” faecal dysbiosis. Rather than
merely reporting dysbiosis and degrees of dysbiosis, future diagnostic tests should distinguish between types of
dysbiosis.
Keywords: Dysbiosis, Irritable bowel syndrome, Metformin, Microbiota, Non-nutritive sweeteners; obesity
Background
The gut microbiota interferes with the mucosal immune
system, the cytokine secretion, the intestinal permeabil-
ity, the secretion of mucus, antimicrobial peptides and
IgA, and the production of metabolites and other
unknown factors. Gut dysbiosis, defined as an imbalance
or deviation from the normal composition of the
microbiota, might be either beneficial (good) due to im-
proved immune system, increased anti/pro inflammatory
cytokine ratio etc., or deleterious (bad). Dysbiosis has
been associated with and mentioned as a causal factor
for obesity in humans [1, 2]. Dysbiosis has also been
suggested as a causal factor for insulin resistance, glu-
cose intolerance and type 2 diabetes, which are common
comorbidities in in subjects with morbid obesity [1, 3].
These types of dysbiosis are “bad”.
Both the diet and drugs influence the faecal microbiota
[4–7]. Metformin has anti-hyperglycemic and weight-redu-
cing effects, which are beneficial in subjects with obesity [8–
10]. The effects depend in part on the altering of the gut
microbiome [11–13]. The metformin-induced dysbiosis,
therefore, contributes to the therapeutic effects and is re-
ferred to as “good” dysbiosis.
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To prevent weight gain and facilitate weight reduction,
subjects with obesity have a high intake of non-nutritive
sweeteners (NNS) [14]. NNS induce glucose intolerance
by altering the gut microbiota and has been linked to
obesity by the obesity-associated metabolic changes [15–
17]. Therefore, the dysbiosis associated with NNS seems
to be unfavourable and is henceforth denoted as “bad”
dysbiosis.
Irritable bowel syndrome (IBS), a common comorbid-
ity in subjects with morbid obesity, is one of many disor-
ders associated with alterations in the gut microbiota
(“bad” dysbiosis) [18–21]. In all, dysbiosis is associated
with various disorders. According to the recently pro-
posed “Anna Karenina principle” for animal micro-
biomes, the microbiome varies more in dysbiotic than in
healthy subjects, and such variations might be separated
into “good” and “bad” dysbioses [22].
Today’s knowledge about dysbiosis is limited, the diag-
nostic tests are complicated and expensive, and the clin-
ical utility is questionable. Knowledge of “good” and
“bad” dysbioses might have clinical implications, such as
normalising or preventing the “bad” dysbioses and pre-
serving the “good” ones.
A simplified test for faecal dysbiosis based upon 54
DNA probes targeting gut bacteria has been marketed in
Europe and USA (GA-map™ Dysbiosis Test, manufac-
tured by Genetic Analysis, Oslo, Norway) [23, 24].
In this study, the primary aims were to assess the com-
mercially available dysbiosis test’s ability to detect faecal
dysbiosis in subjects with morbid obesity and to detect
dysbiosis associated with other variables, primarily met-
formin, NNS, diabetes, IBS and gastrointestinal symp-
toms. Based on the hypothesis that the dysbioses
associated with the use of metformin and NNS differed
[22], the secondary aims were to use the results of the
dysbiosis test to explore alternative scoring algorithms
to detect differences between the dysbiosis associated
with metformin and NNS. The alternative scoring was
validated in a new cross-sectional study.
Methods
Study design
Exploratory analyses were performed in one cross-sectional
study (the test group) and validated in another
cross-sectional study (the validation group).
In the test group, the dysbiosis test’s ability to detect
dysbiosis related to obesity, diabetes, IBS, the severity of
gastrointestinal symptoms and use of NNS and metfor-
min were studied. If dysbiosis was detected, explorative
analyses were performed to detect differences between
the dysbioses related to metformin (the “good” dysbiosis)
and NNS (the “bad” dysbiosis) and to work out an Alter-
native Dysbiosis Index that distinguished between the
“good” and “bad” dysbioses. Some of the results were
validated in the validation group.
Subjects
From December 2012 to September 2014, consecutive
subjects aged 18–65 years with morbid obesity (defined
as BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with obesity-related
complications) were included in the test group at
Innlandet Hospital Trust, Gjøvik, Norway. At Lovisen-
berg Diaconal Hospital’s outpatient clinic for gastrointes-
tinal disorders, consecutive subjects above 18 years of
age with IBS were from April 2013 to October 2014 in-
cluded in the validation group. At both centres, a med-
ical history was taken, paper-based questionnaires were
filled in by the patients, a physical examination was per-
formed, and blood and faecal samples were collected.
Supplementary examinations were performed at the doc-
tors’ discretion. Subjects with serious somatic and psy-
chiatric disorders (if judged as unrelated to obesity in
the test group) were excluded because they could con-
found the evaluation of dysbiosis, and subjects with pre-
vious major abdominal surgery including bariatric
surgery were excluded to ascertain the diagnosis of IBS.
In addition, subjects not delivering faecal samples, sub-
jects with incompletely filled in food frequency question-
naires (FFQ) were excluded from the test group, and
subjects using antibiotics the last month or with a
13C-D-Xylose breath test indicating malabsorption were
excluded from the validation group. At both centres,
trained personnel was responsible for the care of the pa-
tients and the practical work.
Variables
Gender, age (years), body weight (kg), height (meter),
body mass index (BMI, kg/m2), smoking habits (never /
previously / daily smokers), and present or previous
somatic disorders including hypertension, diabetes, and
hypothyroidism (yes / no) were noted. Irritable Bowel
Syndrome (IBS) was diagnosed with a validated Norwe-
gian translation of the Rome III criteria, and the degree
of gastrointestinal complaints with Irritable Bowel Sever-
ity Scoring System (IBSSS) [25]. The use of metformin,
statins, and thyroxin was recorded. A range of haemato-
logical and biochemical blood tests including vitamins
and minerals were analysed.
The dietary intake of micro- and macro nutrients, en-
ergy, and NNS were assessed with an FFQ prepared, val-
idated and analyzed by the Department of Nutrition at
the University of Oslo, Norway. The analyses were per-
formed with their in-house calculation program (KBS,
version 7.3, food database AE-14) based on the official
Norwegian food composition table from 2016 [26]. The
intake of NNS was calculated pragmatically since the
FFQ did not specify the type or amount of NNS in the
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beverages. One unit of NNS was defined as 100 ml
NNS-containing beverage (divided into carbonated and
non-carbonated beverage) which was considered equal
to the sweetening of sugar-containing beverages with
10% of sugar (10 g/100 ml). Two NNS tablets/teaspoons
for use in tea or coffee were judged as equal to 100 ml
NNS in beverages. The unit (100 ml beverages or two
tablets/teaspoons) could easily be calculated since the
subjects reported the intake in litre and glasses, and the
unit is easily understood. Intakes of NNS from other
sources than beverages and tablets/teaspoons used in
beverages were not recorded. Sugar alcohols and
naturally-derived sweeteners not defined as NNS were
not included. In addition to the associations between
dysbiosis and NNS, the associations between dysbiosis
and sugar-containing beverages and the absolute and
relative amounts of macronutrients were analysed.
The faecal microbiota was analysed with the CE
marked GA-map™ Dysbiosis Test (Genetic Analysis AS,
Oslo, Norway) [23]. The test has both a US (Patent No.
9243297) and European patent (Patent No. 2652145) for
its technology governing the oligonucleotide probe set
and methods of microbiota profiling [24]. It uses 54
oligonucleotide probes targeting the 16S rRNA gene at
different bacterial taxonomic levels and scores the rela-
tive abundance of each bacteria compared to the distri-
bution in a reference population (score −3 to 3). The
overall result is given as the Dysbiosis Index (DI) with
scores 1 to 5, where values above 2 indicate a microbiota
profile that differs from the reference population (i.e.
dysbiosis). Exploratory analyses were performed to show
differences between metformin and NNS in the relative
abundance of one or more of the bacteria measured on
the score from −3 to 3. The detected differences were
summarised in the ADI.
Statistics
The results have been reported as mean (SD), median
(range), and number (proportion in percentage). Com-
parisons between groups were analysed with chi-square
tests, t-test, Mann-Whitney U-test, Pearson’s and Spear-
man’s correlation analyses depending on type and distri-
bution of the data. Independent predictors of dysbiosis
were assessed with linear regression analyses includ-
ing gender, BMI and all variables significantly associ-
ated with dysbiosis in the univariable analyses
followed by stepwise forward regression analyses. The
results of the linear regression analyses are given as
B-value with 95% confidence interval (CI), p-value
and partial correlation (pc). The analyses were
performed with IBM SPSS Statistics for Windows,
Version 25.0. Armonk, NY: IBM Corp. p-values < 0.05
were judged as statistically significant.
Results
The test group
Out of 350 consecutive subjects visiting the obesity unit,
90 (76 women and 14 men with a mean age of 44.7 years
(SD 8.6) and BMI 41.8 kg/m2 (SD 3.6)) were included in
the test group. The reasons for the exclusion of 260 sub-
jects are given in Fig. 1. Table 1 gives the participants’
characteristics in detail divided into subjects with and
without dysbiosis. Dysbiosis was present in 59 (66%) of
the subjects; the mean DI score was 3.0 (SD 1.3). The DI
scores 1–5 were present in 16 (18%), 15 (17%), 30 (33%),
13 (14%), and 16 (18%) subjects respectively. The main
finding was the associations between dysbiosis and dia-
betes, metformin and NNS (all p-values < 0.01). There
were no significant associations with either IBS or IBSSS.
Table 1 gives all the associations except for the associa-
tions with the relative amounts of the macronutrients
since there were no significant associations with these
variables. Figure 2 shows the associations between the
DI and the use of NNS and metformin and IBSSS.
Explorative analyses revealed significant differences be-
tween the dysbiosis related to NNS and metformin.
Compared to NNS, the dysbiosis related to metformin
was characterised by a relative abundance of the bacteria
Alistipes, Proteobacteria and Shigella spp. & Escherichia
spp., and a relative scarcity of Bacteroides fragilis, Rumi-
nococcus gnavus, Bacteroides spp. & Prevotella spp., and
Dialister invisus. The signs of the scores for the bacteria
with a relative scarcity were changed. Then the scores for
the seven bacteria were summed up and adjusted to the
Alternative Dysbiosis Index (ADI) with scores from −14 to
14; positive scores were associated with the use of metfor-
min (the “good” dysbiosis) and negative scores with the
use of NNS (the “bad” dysbiosis). The mean ADI score
was −0.8 (SD 2.8). Table 1 gives all associations between
the patients’ characteristics and the ADI. Figure 3 shows
the positive association between the ADI and metformin
and the negative associations with NNS and IBSSS, which
were the main and statistically significant findings.
Multivariable analyses were used to study independent
predictors of DI and ADI. These analyses included gen-
der and BMI and all variables with a significant associ-
ation with either DI or ADI. Diabetes and metformin
were highly correlated (r = 0.80). Because the associa-
tions between metformin and DI and ADI were signifi-
cantly higher than between diabetes and DI and ADI,
diabetes was excluded from the analyses. Separate multi-
variable analyses (not shown) of the associations be-
tween DI and ADI on one side and total energy intake
and the absolute and relative intake of macronutrients
on the other side showed that the absolute intake of
starch was the only independent predictor of DI and
ADI. Therefore, starch was the only nutrient included in
the multivariable analyses.
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The results of the multivariable analyses with all vari-
ables in the equation and the stepwise forward analyses
are given in Table 2. The main findings were the positive
associations between DI and use of metformin and NNS,
the positive association between ADI and metformin
(the “good” dysbiosis), and the negative associations be-
tween ADI and NNS and IBSSS (the “bad” dysbiosis).
The validation group
Fifty-six women and seven men with a mean age of 38.8
(SD 12.4) years were included in the validation group.
The mean ADI and IBSSS scores were −1.68 (SD 2.26)
and 287 (SD 79). No one used metformin, and informa-
tion about NNS was not available. Table 3 gives the as-
sociations between the ADI and IBS and IBSSS in the
test group and the validation groups with comparisons
between the groups. IBS and IBSSS were associated with
negative ADI scores. The significant associations be-
tween ADI and IBSSS in the two groups were of the
same order.
Discussion
Based partly on the same data material and the same
dysbiosis test, we have previously published that dysbio-
sis was prevalent in subjects with morbid obesity and
not associated with IBS [18]. The new findings in this
study were that dysbiosis measured with the producer’s
DI was associated with the use of metformin and NNS,
but not with the severity of gastrointestinal symptoms
measured as IBSSS. Dysbiosis associated with metformin
and NNS have been reported in other studies with more
complex, resource demanding, and costly methods [4, 5,
11, 12, 15, 27]. Another new finding was that alternative
analyses of the producer’s results allowed separations of
types of dysbioses; one type was associated with the use
of metformin (“good” dysbiosis) and one with IBS and
the use of NNN (“bad” dysbiosis). Today’s lack of know-
ledge about the clinical significance of dysbiosis mea-
sured with this test, and the test’s seemingly inability to
differentiate between types of dysbioses nearly eliminates
its clinical usability. Hopefully, further research will clar-
ify the clinical consequences of dysbiosis and types of
dysbioses measured with this test.
Dysbiosis has been attributed a causal role of obesity
in animals. The clinical significance of dysbiosis in
humans with obesity and for obesity associated disorders
such as insulin resistance, glucose intolerance and type 2
diabetes is less clear [1–3, 28]. The relatively weak asso-
ciations between obesity and dysbiosis and the large
interpersonal variation hamper the interpretation of the
results [28]. The variations might indicate different types
of dysbiosis, e.g. “good” and “bad”. Theoretically, one
type of dysbiosis might have favourable and unfavour-
able effects referring to different outcomes.
Fig. 1 A flowchart of the subjects in the study
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Neither has the clinical significance of dysbiosis associ-
ated with the diet and use of drugs been clarified [4–7].
Metformin is a drug of particular interest in subjects
with morbid obesity because of the anti-hyperglycemic,
insulin sensitising, and weight-reducing effects [8, 9].
The drug’s effect on the faecal microbiota is well estab-
lished [4, 5, 11, 12].The mechanisms by which metfor-
min exerts its effects have until recently been uncertain
[8, 29]. Importantly, intravenous administration has no
effect in either non-diabetic subjects or subjects with type
2 diabetes [30, 31]. The glucose tolerance improved in
germ-free mice given faeces from metformin-treated mice,
indicating that the effect in part depends on alteration of
the gut microbiome [11, 12]. The metformin-induced dys-
biosis is, therefore, “good” for the effect of metformin.
The favourable and unfavourable effects of NNS on
body weight, lifestyle, and metabolism is continuously
discussed, and the literature is probably heavily biased
Fig. 2 Associations between the Dysbiosis Index and the main variables. NNS Q1, NNS Q2, NNS Q3, NNS Q4: Intake of Non-Nutritive Sweeteners
divided into quartiles. Met: Metformin. IBSSS: Irritable Bowel Severity Scoring System. The results for NNS and Met are given as mean with 95% CI.
The associations are given as Pearson’s and Spearman's correlation coefficients (r and rho) and significance value (p-value)
Fig. 3 Associations between the Alternative Dysbiosis Index and the main variables. NNS Q1, NNS Q2, NNS Q3, NNS Q4: Intake of Non-Nutritive
Sweeteners divided into quartiles. Met: Metformin. IBSSS: Irritable Bowel Severity Scoring System. The results for NNS and Met are given as mean
with 95% CI. The associations are given as Pearson’s and Spearman's correlation coefficients (r and rho) and significance value (p-value)
Farup et al. BMC Obesity  (2018) 5:30 Page 6 of 10
Ta
b
le
2
Pr
ed
ic
to
rs
of
D
ys
bi
os
is
In
de
x
an
d
A
lte
rn
at
iv
e
D
ys
bi
os
is
In
de
x
(li
ne
ar
re
gr
es
si
on
an
al
ys
es
)
In
de
pe
nd
en
t
pr
ed
ic
to
rs
D
ep
en
de
nt
:D
I(
al
lv
ar
ia
bl
es
)
D
ep
en
de
nt
:D
I(
st
ep
w
is
e
fo
rw
ar
d)
D
ep
en
de
nt
:A
D
I(
al
lv
ar
ia
bl
es
)
D
ep
en
de
nt
:A
D
I(
st
ep
w
is
e
fo
rw
ar
d)
B
(9
5%
C
I)
p-
va
lu
e
pc
B
(9
5%
CI
)
p-
va
lu
e
pc
B
(9
5%
C
I)
p-
va
lu
e
pc
B
(9
5%
CI
)
p-
va
lu
e
pc
G
en
de
r
(fe
m
al
e/
m
al
e)
1.
01
(0
.1
7;
1.
85
)
0.
19
0.
27
5
−
0.
96
(−
2.
61
;0
.7
0)
0.
25
−
0.
13
7
A
ge
(y
ea
rs
)
−
0.
01
(−
0.
05
;0
.0
2)
0.
46
−
0.
08
8
0.
05
(−
0.
02
;0
.1
3)
0.
15
0.
17
2
0.
07
(0
.0
1;
0.
13
)
0.
03
3
0.
24
1
BM
I(
kg
/m
2)
−
0.
00
(−
0.
08
;0
.0
8)
0.
95
−
0.
00
7
−
0.
07
(−
0.
23
;0
.0
9)
0.
38
−
0.
10
5
Sm
ok
in
g
(n
ev
er
/
pr
ev
io
us
ly
/d
ai
ly
)
0.
36
(−
0.
08
;0
.8
0)
0.
10
0.
19
3
−
0.
67
(−
1.
53
;0
.1
9)
0.
12
−
0.
18
3
C
of
fe
e
(c
up
s/
da
y)
−
0.
02
(−
0.
16
to
0.
13
)
0.
79
−
0.
03
2
0.
02
(−
0.
26
;0
.3
1)
0.
87
0.
02
0
IB
SS
S
(8
6)
0.
00
(−
0.
00
2;
0.
00
4)
0.
47
0.
08
6
−
0.
00
6
(−
0.
01
;0
.0
0)
0.
03
9
−
0.
24
4
−
0.
01
(−
0.
01
;−
0.
00
)
0.
02
2
−
0.
25
8
M
et
fo
rm
in
0.
99
(0
.2
2;
1.
75
)
0.
01
2
0.
29
5
1.
11
(0
.4
2;
1.
80
)
0.
00
2
0.
33
9
2.
53
(1
.0
4;
4.
03
)
0.
00
1
0.
37
4
2.
32
(0
.9
3;
3.
71
)
0.
00
1
0.
35
4
W
at
er
(u
ni
t
a )
0.
00
(−
0.
02
;0
.0
2)
0.
98
−
0.
00
2
−
0.
01
(−
0.
04
;0
.0
3)
0.
76
−
0.
03
7
C
ar
b.
be
v.
w
/
su
ga
r
(u
ni
t
a )
0.
20
(−
0,
05
;0
.4
5)
0.
12
0.
18
6
0.
13
(−
0.
37
;0
.6
3)
0.
60
0.
06
2
To
ta
lN
N
S
(u
ni
t
a )
0.
03
5
(−
0.
00
;0
.0
7)
0.
05
4
0.
22
8
0.
04
(0
.0
1;
0.
07
)
0.
00
5
0.
31
1
−
0.
08
(−
0.
15
;−
0.
01
)
0.
02
4
−
0.
26
6
−
0.
10
(−
0.
16
;−
0.
04
)
0.
00
1
−
0.
36
2
St
ar
ch
(g
/d
ay
)
−
0.
00
(−
0.
01
;0
.0
0)
0.
36
−
0.
10
9
−
0.
00
(−
0.
02
;0
.0
1)
0.
53
−
0.
07
6
D
ID
ys
bi
os
is
In
de
x,
A
D
IA
lte
rn
at
iv
e
D
ys
bi
os
is
In
de
x,
IB
SS
S
Irr
ita
bl
e
Bo
w
el
Se
ve
rit
y
Sc
or
in
g
Sy
st
em
,N
N
S
N
on
-N
ut
rit
iv
e
Sw
ee
te
ne
rs
,p
c
pa
rt
ia
lc
or
re
la
tio
n,
Ca
rb
.b
ev
:C
ar
bo
na
te
d
be
ve
ra
ge
s.
a O
ne
un
it
is
10
0
m
lb
ev
er
ag
es
w
ith
N
N
S
or
2
ta
bl
et
s
N
N
S
fo
r
co
ff
ee
/t
ea
G
en
de
r
an
d
BM
Ia
nd
al
lv
ar
ia
bl
es
si
gn
ifi
ca
nt
ly
as
so
ci
at
ed
w
ith
ei
th
er
D
Io
f
A
D
Ii
n
th
e
un
iv
ar
ia
te
an
al
ys
es
(a
ge
,s
m
ok
in
g
ha
bi
ts
,c
of
fe
e,
IB
SS
S,
M
et
fo
rm
in
,t
ot
al
N
N
S,
st
ar
ch
)
w
er
e
in
cl
ud
ed
as
pr
ed
ic
to
rs
of
D
Ia
nd
A
D
Ii
n
th
e
re
gr
es
si
on
an
al
ys
es
.T
he
re
as
on
s
fo
r
ex
cl
us
io
n
of
di
ab
et
es
an
d
so
m
e
nu
tr
ie
nt
s
ar
e
ex
pl
ai
ne
d
in
th
e
te
xt
.A
ll
th
e
va
ria
bl
es
w
er
e
in
cl
ud
ed
in
th
e
fir
st
st
ep
,a
nd
th
en
st
ep
w
is
e
fo
rw
ar
d
re
gr
es
si
on
an
al
ys
es
w
er
e
pe
rf
or
m
ed
Ita
lic
iz
ed
p-
va
lu
es
ar
e
st
at
is
tic
al
ly
si
gn
ifi
ca
nt
Farup et al. BMC Obesity  (2018) 5:30 Page 7 of 10
[14, 32–35]. The dysbiosis caused by NNS induces glu-
cose intolerance and has been linked to obesity by the
obesity-associated metabolic changes [15–17]. Therefore,
the NNS associated dysbiosis is probably “bad” for sub-
jects with morbid obesity.
IBS is one among many disorders that has been associated
with alterations in the gut microbiota [18–21]. The dysbiosis
in subjects with IBS is a “bad” dysbiosis since faecal micro-
biota transplantation may normalise the microbiota and im-
prove symptoms [36]. In all, there are several types of
dysbiosis that might be separated into “good” and “bad”.
The producer’s test response does not differentiate
between types of dysbiosis. The ADI based on simple
explorative analyses of available results in the producer’s
report could easily separate the “good” metformin-type
dysbiosis from the “bad” NNS-type dysbiosis. The
ADI-score was adjusted so that “good” and “bad” dysbiosis
had positive and negative scores respectively. If the results
are reproducible, and the dysbiosis test allows construc-
tion of other clinically relevant dysbiosis indexes, the po-
tential usefulness of the test increases markedly.
The ADI was not constructed to explore dysbiosis
associated with IBS and gastrointestinal complaints. The
negative correlations between ADI and IBS and gastro-
intestinal symptoms were therefore new and interesting
findings, which were confirmed with unadjusted and ad-
justed analyses in the validation group. The findings are in
accordance with other reports indicating associations be-
tween IBS and dysbiosis [19–21]. The ADI could be a test
for detection of “bad” dysbiosis in subjects with IBS and
gastrointestinal complaints and replace complex, resource
demanding and costly 16S gene sequencing.
Further research, aiming at enlarging the producer’s
test response with the specification of the type of dysbio-
sis related to dietary factors, drugs, disorders and dis-
eases (e.g. metformin- or NNS-like, or “good” or “bad”)
is desirable. Specified results might predict response to
treatment, e.g. antibiotics and other drugs, probiotics,
prebiotics, diet, and faecal microbiota transplant. Treat-
ment aiming at prevention or normalising of a “bad”
dysbiosis or induction of a “good” dysbiosis could
change the treatment of a range of disorders [37].
Strengths and limitation
The test group and the validation group were consecu-
tive subjects representative of subjects referred to out-
patient clinics for morbid obesity and gastrointestinal
complaints respectively. Because the ADI was con-
structed to detect differences between metformin and
NNS, the significant differences between the ADI scores
for metformin and NNS were expected. It was neverthe-
less pleasing that the ADI could be constructed so easily.
The most impressive findings were the associations be-
tween IBS and IBSSS and the negative ADI score. The
ADI was not constructed to find these differences, and
they were not detected with the producer’s result report.
It was a strength that these findings were confirmed in
the validation group, which substantiates that a negative
ADI indicates a “bad” NNS- or IBS-like dysbiosis.
The external validity could be questioned since the ADI
was based on results from subjects with morbid obesity
who might have a high prevalence of dysbiosis also with-
out having gastrointestinal comorbidity and use of metfor-
min and NNS. The exclusion of subjects using antibiotics
the last month might have been a too short period.
Conclusions
A commercially available test for faecal dysbiosis showed a
high prevalence of dysbiosis in subjects with morbid
obesity, particularly in users of metformin and NNS, but
no association with gastrointestinal complaints. An ADI
based on explorative analyses of the results from the test
could differentiate between the “good” dysbiosis associated
with metformin and the “bad” dysbiosis associated with
NNS. The “bad” dysbiosis was also associated with gastro-
intestinal symptom severity. The associations between IBS
and gastrointestinal symptom severity were confirmed in
an independent validation group, indicating that ADI
might be a valid diagnostic tool for the diagnosis of
IBS-associated dysbiosis. Rather than merely reporting
dysbiosis and degrees of dysbiosis, diagnostic tests for fae-
cal dysbiosis should separate between types of dysbiosis.
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